112 related articles for article (PubMed ID: 8603000)
1. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes.
Oriani A; Annaloro C; Soligo D; Pozzoli E; Cortelezzi A; Lambertenghi Deliliers G
Br J Haematol; 1996 Feb; 92(2):360-4. PubMed ID: 8603000
[TBL] [Abstract][Full Text] [Related]
2. CD34 immunohistochemical staining of bone marrow biopsies in myelodysplastic syndromes.
Min YH; Lee ST; Min DW; Kim TS; Lee CH; Lee BK; Hahn JS; Ko YW
Yonsei Med J; 1995 Mar; 36(1):1-8. PubMed ID: 7537931
[TBL] [Abstract][Full Text] [Related]
3. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes.
Soligo DA; Oriani A; Annaloro C; Cortelezzi A; Calori R; Pozzoli E; Nosella D; Orazi A; Deliliers GL
Am J Hematol; 1994 May; 46(1):9-17. PubMed ID: 7514357
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.
Lambertenghi-Deliliers G; Annaloro C; Oriani A; Soligo D; Pozzoli E; Polli EE
Ann Hematol; 1993 Feb; 66(2):85-91. PubMed ID: 8448244
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
[TBL] [Abstract][Full Text] [Related]
6. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes.
Baur AS; Meugé-Moraw C; Schmidt PM; Parlier V; Jotterand M; Delacrétaz F
Eur J Haematol; 2000 Feb; 64(2):71-9. PubMed ID: 10997326
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and prognostic significance of CD34 expression in bone marrow biopsies in myelodysplastic syndrome].
Savić A; Rajić N; Vlaisavljević N; Cemerikić-Martinović V; Popović S
Med Pregl; 2010; 63(7-8):487-91. PubMed ID: 21446135
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes.
Lambertenghi Deliliers G; Annaloro C; Soligo D; Oriani A
Leuk Lymphoma; 1998 Jan; 28(3-4):231-9. PubMed ID: 9517495
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
10. Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias.
Dunphy CH; O'Malley DP; Perkins SL; Chang CC
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):154-9. PubMed ID: 17525626
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
12. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
13. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
14. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment.
Orazi A; Cattoretti G; Soligo D; Luksch R; Lambertenghi-Deliliers G
Leukemia; 1993 Jun; 7(6):838-47. PubMed ID: 7684797
[TBL] [Abstract][Full Text] [Related]
16. A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes.
Vido-Marques JR; Reis-Alves SC; Saad STO; Metze K; Lorand-Metze I
Sci Rep; 2020 Nov; 10(1):20281. PubMed ID: 33219285
[TBL] [Abstract][Full Text] [Related]
17. High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.
Tang G; Wang SA; Menon M; Dresser K; Woda BA; Hao S
Leuk Res; 2011 Jun; 35(6):766-70. PubMed ID: 21367453
[TBL] [Abstract][Full Text] [Related]
18. Significance of CD34(-) and CD34(+) cell apoptosis and proliferation in bone marrow of patients with MDS and their impact on survival.
Xia B; Guo Q; Zhao DD; Zhao HF; Han XP; Wang H; Wu XX; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1392-7. PubMed ID: 23257440
[TBL] [Abstract][Full Text] [Related]
19. CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS.
Cha CH; Park CJ; Chi HS; Seo EJ; Jang S; Cho YU; Lee KH; Lee JH; Lee JH; Im HJ; Seo JJ
Ann Lab Med; 2014 Nov; 34(6):426-32. PubMed ID: 25368817
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.
Ríos A; Cañizo MC; Sanz MA; Vallespí T; Sanz G; Torrabadella M; Gomis F; Ruiz C; San Miguel JF
Br J Haematol; 1990 May; 75(1):26-33. PubMed ID: 2375920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
